A B S T R A C T
Background: Hypoparathyroidism, deafness and renal dysplasia (HDR) syndrome is a rare autosomal dominant disorder, secondary to mutations in the GATA-3 gene. Due to its wide range of penetrance and expressivity, the disease may not always be recognized. We herein describe clinical and genetic features of patients with HDR syndrome, highlighting diagnostic clues. Methods: Medical records of eight patients from five unrelated families exhibiting GATA-3 mutations were reviewed retrospectively, in conjunction with all previously reported cases. Results: HDR syndrome was diagnosed in eight patients between the ages of 18 and 60 years. Sensorineural deafness was consistently diagnosed, ranging from clinical hearing loss since infancy in seven patients to deafness detected only by audiometry in adulthood in one single patient. Hypoparathyroidism was present in six patients (with hypocalcaemia and inaugural seizures in two out of six). Renal abnormalities observed in six patients were diverse and of dysplastic nature. Three patients displayed nephrotic-range proteinuria and reached end-stage renal disease (ESRD) between the ages of 19 and 61 years, whilst lesions of focal and segmental glomerulosclerosis were histologically demonstrated in one of them. Interestingly, phenotype severity differed significantly between a mother and son within one family. Five new mutations of GATA-3 were identified, including three missense mutations affecting zinc finger motifs [NM_001002295.1: c.856A>G (p.N286D) and c.1017C>G (p.C339W)] or the conserved linker region [c.896G>A (p.R299G)], and two splicing mutations (c.924þ4_924þ19del and c.1051-2A>G). Review of 115 previously reported cases of GATA-3 mutations showed hypoparathyroidism and deafness in 95% of patients, and renal abnormalities in only 60%. Overall, 10% of patients had reached ESRD. Conclusions: We herein expand the clinical and mutational spectrum of HDR syndrome, illustrating considerable interand intrafamilial phenotypic variability. Diagnosis of HDR should be considered in any patient with hypoparathyroidism and deafness, whether associated with renal abnormalities or not. HDR diagnosis is established through identification of a mutation in the GATA-3 gene.
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I N T R O D U C T I O N
Human hypoparathyroidism, sensorineural deafness and renal dysplasia (HDR) syndrome is a rare autosomal dominant disorder [1] . The syndrome primarily results from haploinsufficiency of the GATA-3 gene, located on chromosome 10p15 (OMIM146255). GATA-3 encodes the transcriptional regulator glutamyl amidotransferase subunit A (GATA-3) [2, 3] , which plays an essential role in embryonic development of the parathyroids, inner ear and kidneys. GATA-3 contains an N-terminal finger domain (ZnF1) that physically interacts with a variety of nuclear proteins, including the multi-type zinc finger Friends of GATA (FOG-1 and FOG-2), and a C-terminal finger essential for DNA binding (ZnF2) [4, 5] .
Like other genes involved in human development, GATA-3 haploinsufficiency displays a wide range of penetrance. This may thus cause HDR syndrome to be under-recognized. To cast light on the clinical and mutational spectrum of the syndrome, we hereby report on eight patients from five families. Four of them presented a clinical picture quickly recognized to be HDR, whilst the others were diagnosed either during family screening or by chance. We identified five distinct new mutations in the GATA-3 gene and discuss their resulting functional consequences. We also provide a comprehensive overview of the clinical characteristics of 115 previously reported HDR cases, highlighting diagnostic clues indicative of the syndrome.
Patients
The medical records of eight patients (three male and five female) exhibiting genetically proven HDR syndrome and from five unrelated families were reviewed retrospectively. Sanger sequencing was performed on all GATA-3 exons and the results compared with the published sequence (GenBank reference number NM_001002295.1).
In Patient #1, the effect of detected GATA-3 deletion on RNA splicing was studied.
GATA-3 is known to exhibit alternative splicing transcripts [6] . RNA was extracted from white blood cells and reversetranscribed. Specific primers were designated in the GATA-3 exons 3 and 5, whilst cDNA was used as a template for PCR amplification. Forward fluorescence-labelled primer was employed and PCR products were separated via capillary electrophoresis in order to measure sizes and ratios using the Agilent 2100 Bioanalyzer.
Review
Clinical data from all previously reported and genetically proven cases of a GATA-3 mutation were analysed. Relevant studies written in English were identified using MEDLINE.
R E S U L T S

Patients
Clinical characteristics at the time of diagnosis are presented in Table 1 and family pedigrees in Figure 1 .
Family 1 (Patients #1 and #2). Patient #1 (II.2) had had a history of congenital bilateral sensorineural deafness and polyuria-polydipsia with enuresis since childhood. He had been diagnosed at the age of 18 years with severe chronic kidney disease (CKD) (creatinine level of 8 mg/dL) during workup for seizures secondary to hypocalcaemia. Laboratory examinations revealed severe hypocalcaemia (4.9 mg/dL), low serum intact parathyroid hormone (iPTH) (17 pg/mL; normal range 20-95 pg/mL) and proteinuria of 5 g/day with a bland sediment. Ultrasound imaging showed symmetrically hypotrophic kidneys with regular contours. Cysto-urethrography revealed discrete left-sided vesicoureteral reflux (VUR). Consequently, the suspected diagnosis was HDR. Blood and urine tests performed in his father and two sisters appeared normal. Intermittent haemodialysis was initiated at age 19 years, and kidney transplantation from a deceased donor was performed 2 years later.
Patient #2 (I.2) is the mother of Patient #1. Her medical history likewise showed severe congenital bilateral sensorineural deafness. Patient #2's parents were not known to be affected by deafness, and her father's history included nephrectomy secondary to tuberculosis. Both parents died of non-renal causes. At the age of 37 years, due to recurrent cystitis and back pain, Patient #2 underwent urinary tract imaging, thus revealing right-sided VUR, an atrophic right kidney and malrotation of the left kidney, with features of chronic pyelonephritis. Laboratory examinations performed at the age of 58 years (family screening when Patient #1 was diagnosed with HDR syndrome), revealed CKD with a serum creatinine level of 1.6 mg/ dL, corresponding to a Modification of Diet in Renal Diseaseestimated glomerular filtration rate (eGFR) of 35 mL/min/1.73 m 2 . Serum calcium and phosphorus levels were within the normal range (8.8 and 3.7 mg/dL, respectively), as was the serum iPTH level (44 pg/mL; normal range 16-81 pg/mL). Urinalysis showed mild proteinuria (440 mg/day) with a bland sediment.
Genetic analysis in Patients #1 and #2 showed heterozygous deletion of 16 nucleotides (c.924þ4_924þ19del) lying within the exon-intron 4 junction in the GATA-3 gene (Figure 2 ). The effect of this deletion on RNA splicing was studied (Materials and methods section). Three isoforms were expected and observed in the control individual, including two functional transcripts (NM_00102295.1 and NM_002051.2), distinct through the presence of an additional residue at position 260 (T1 and T2), and a short transcript-lacking exon 4 (T3). In this case, the mutation lying around the 5 0 splice site of exon 4 caused incorrect splicing with a significant increase of the shortest fragment (T3) ( Figure 2B ). The aforementioned deletion was not observed in Patient #1's two unaffected sisters ( Figure 1 ).
Family 2 (Patient #3). Patient #3 (II.
3) had a history of hypocalcaemia (5.6 mg/dL) and hypoparathyroidism (iPTH 7 pg/mL; normal range 16-81 pg/mL), detected at the age of 54 years during workup following a road accident. He had no siblings, his father was unknown and his mother had died of leukaemia at the age of 80 years. He was referred at the age of 56 years due to CKD (creatinine 1.8 mg/dL, eGFR 39 mL/min/1.73 m 2 and proteinuria 1 g/day). No past blood or urine tests were available for comparison. A computed tomography (CT) scan of the abdomen showed normal-sized kidneys with a lower right pole cyst. HDR syndrome was suspected, despite the lack of clinical deafness. Audiometry revealed high-frequency, bilateral, asymmetrical, sensorineural hearing loss (right 60 and left 50 dB).
Genetic testing showed a c.896G>A change responsible for the loss of the highly conserved arginine 299 in the vicinity of the first DNA-binding domain ( Figure 2A ). The c.896G>A was not annotated as polymorphic in dbSNP137 Build 141 [7] , nor was it present in 1128 control individuals from the 1000 Genomes database [8] and Exome Variant Server (University of Washington) [9] , indicating an extremely low allele frequency in the healthy population. The algorithms PolyPhen-2, SNAP and Mutation Taster predicted this change to cause disease.
Family 3 (Patient #4). During the first year of her life, Patient #4 (II.3) had presented recurrent urinary tract infections due to bilateral VUR requiring surgical correction. Bilateral sensorineural hearing loss was likewise diagnosed. At age 4 years, she had seizures and tetany secondary to severe hypocalcaemia (5.9 mg/dL) and hypoparathyroidism (iPTH 11 pg/mL; normal range 11-54 pg/mL). Mild proteinuria (1.7 g/day) and renal impairment were observed at age 14 years. At age 21 years, HDR syndrome was strongly suspected. Serum creatinine was 1.7 mg/dL (eGFR 38 mL/min/1.73 m 
A CT scan showed normal-sized kidneys (lengths of 102 and 103 mm, respectively) with bilateral cysts, whilst a kidney biopsy revealed 50% of the glomeruli to be affected by sclerosis, and the other 50% by focal segmental glomerulosclerosis lesions (FSGS). Neither the patient's parents nor brothers had a history of hearing loss or renal abnormalities (systematic ultrasounds were not performed). The patient received a pre-emptive kidney transplant from a live donor (brother) at age 28 years. A heterozygous variant (c.1051-2A>G) was observed in the GATA-3 gene. A-to-G transversion occurred at À2 position within the invariant AG acceptor splice site, which was predicted to lead to mis-splicing and exon 6 skipping (Figure 2A ). Due to its location within a regulatory splice site and validation of its pathogenic effect by all splice analysis software programs, no RNA study was performed.
Family 4 (Patients #5, #6 and #7). Patient #5 (II.1) had a history of alcohol-related cardiomyopathy, as well as bilateral, congenital, sensorineural deafness and hypocalcaemia erroneously attributed to autoimmune hypoparathyroidism. The medical histories of his parents revealed no indication of preexisting hearing loss or renal abnormality, whilst his mother succumbed to breast cancer and his father to anthracosilicosis. The patient was admitted at the age of 54 years with acute pancreatitis secondary to hypercalcemia, associated with moderate CKD (creatinine level of 1.7 mg/dL, eGFR 45 mL/min/1.73 m 2 ). 2: (A) Schematic representation of the GATA-3 genomic structure, mutations and their protein correspondence. Sanger sequencing of all GATA-3 exons and comparison with a published sequence (GenBank reference number NM_001002295.1) identified five new mutations, two of which were missense mutations affecting the two zinc finger domains (in blue). One substitution, the p.N286D, involves a conserved uncharged polar residue within the ZnF1, whilst the second mutation, p.C339W, affects a cysteine residue directly interacting with the Zn 2þ ion within the second finger (ZnF2). The third missense mutation, p.R299G (in red), is located in the conserved basic region (flexible linker) adjacent to ZnF2. The protein sequence alignment of the N-finger domain and the flexible linker encoded by orthologs in humans and other vertebrate species shows the conservation of amino acid R299 (blue background). Multiple alignments were gathered from http://www.ncbi. nlm.nih.gov/homologene/. The fourth variant is a point mutation (c.1051-2A>G) located in the 3 0 splice site of exon 6. This mutation can lead to incorrect splicing and is predicted to result in exon 6 skipping. With respect to the reading frame, this is likely to result in a shorter GATA-3 transcript lacking its C-terminal region (residues 350-444). The fifth mutation is detailed in (B). (B) Representation of the 16-bp deletion and mRNA analysis using RT-PCR. The upper part of the figure illustrates the intronic deletion observed in Family 1 close to the splice donor site of exon 4. The deletion is underlined in red and the exon 4 represented by a blue box. Separation, detection and quantification of PCR products with primers in GATA-3 exons 3 and 5 were performed with the Agilent 2100 Bioanalyzer. The lower electropherogram shows the presence of three distinct peaks detected in both control and patient RNA. The wild-type functional GATA-3 protein results from two transcripts (T1 and T2), which differ by the presence of one additional amino acid, a glutamate, at position 260. The lower band (103 bp) represents the splice product with exon 4 skipping (T3). These transcripts are schematically depicted on the right. GATA-3 is known to have alternative splicing variations in human genome databases including shorter non-coding transcripts. One of them contains part of exons 3 and 5 and corresponds to the T3 transcript. In this case, the mutation disrupts the balance between different isoforms by an increased expression of the non-coding T3 transcript, thus leading to a significantly decreased expression of the functional transcripts (T1 and T2). Hypercalcemia on admission resulted from a recent increase in calcium intake and 1,25-OH vitamin D supplements. Urinalysis revealed mild proteinuria (400 mg/g creatininuria) and a bland sediment. Ultrasonography showed normal-sized, mildly dedifferentiated kidneys with bilateral cysts. Laboratory results performed after calcium and vitamin D supplementation withdrawal indicated hypocalcaemia (6.2 mg/dL), hyperphosphoraemia (7.7 mg/dL) and a low serum iPTH level (<3 pg/ml; normal range 14-72 pg/ml).
Patients #6 (III.1) and #7 (III.2) were the daughters of Patient #5. They were likewise affected by congenital deafness. Workups were carried out in them following their father's HDR diagnosis. The oldest daughter (III.1) exhibited hypocalcaemia (7.1 mg/dL) and low iPTH (17 ng/L; normal range 14-72 ng/L), whilst the second (III.2) presented normal calcemia and iPTH levels. Both daughters displayed normal renal function and renal ultrasounds at the ages of 32 and 29 years, respectively. Genetic analysis of all three patients revealed a new heterozygous substitution c.856A>G (p.N286D) involving a highly conserved amino acid within the zinc finger transcription factor 1 motif (ZnF1) (Figure 2A ). This change was classified as pathogenic by all mutation analysis software programs.
Family 5 (Patient #8). Patient #8 (II.1) presented a medical history of congenital sensorineural deafness, supraventricular tachycardia, congenital interventricular communication, chronic obstructive pulmonary disease, sarcoidosis and CKD. In addition, she had been diagnosed with primary hypoparathyroidism at the age of 30 years and nephrectomized at the age of 43 years due to severe pyonephrosis. Her father had died following heart surgery, whereas her mother had no medical history. The patient was referred to us at the age of 60 years for the management of acute renal function decline occurring in conjunction with pneumonia and heart failure. Her creatinine level was 3.5 mg/dL (eGFR 14 mL/min/1.73 m 2 ) with nephroticrange proteinuria. CT scan showed atrophic left kidney with a single cyst. Haemodialysis was initiated in the acute setting and became chronic a few months later.
Genetic analysis showed heterozygous substitution c.1017C>G (p.C339W) affecting one of the four cysteine residues of the second zinc finger domain (ZnF2), a cysteine that directly interacts with the Zn 2þ ion (Figure 2A ). The patient's only son had no history of deafness and refused workup.
Review of reported cases
To provide an estimate of the frequency of each component of the HDR triad, we reviewed all reported genetically proven cases ( Table 2 ). Details of the analysed studies can be found in the Supplementary data. Hypocalcaemia was present in about 93% of patients and was symptomatic in 64%, with low PTH levels in 61%. Over 95% of patients exhibited audiometrically proven sensorineural deafness, most frequently diagnosed during infancy or childhood. A renal phenotype was observed in about 60% of patients and was extremely diverse, with uni-or bilateral abnormalities such as renal dysplasia, aplasia, hypoplasia, VUR, and pelvicaliceal deformation and cysts. Only 9% of patients were reported to have ESRD.
In rare cases, further manifestations were reported in patients diagnosed with HDR syndrome, including female genital tract malformation, retinitis pigmentosa, growth failure, pyloric stenosis, neurological abnormalities [10] [11] [12] and cardiac abnormalities (secundum atrial septal defect and first-degree atrioventricular block) [13] .
To date, 51 distinct GATA-3 mutations (including singlepoint mutations and minor deletions, as well as major genomic deletions) have been reported in patients with HDR syndrome [13] [14] [15] . Mutation sites varied and spanned the entire gene [11, 16] .
D I S C U S S I O N
Our study concerned eight affected patients from five unrelated families presenting with HDR syndrome, along with a review of 115 previously reported cases. We herein expand the clinical and mutational spectrum of the syndrome and illustrate considerable inter-and intrafamilial phenotypic variability.
Hypoparathyroidism is probably the most specific symptom of HDR syndrome, reportedly absent in only 5-7% of patients affected by a GATA-3 mutation (Table 2 and Ali et al. [16] ). This symptom presents the broadest individual variability, as serum calcium levels range from very low to normal, with symptomatic hypocalcaemia (mainly seizures and tetany) in 64% of patients (Table 2) . Undetectable or inappropriately normal serum concentrations of PTH are the most striking laboratory feature. Hypoparathyroidism is a strong indicator of HDR syndrome, as it is caused by few other disorders (genetic, autoimmune and parathyroid gland infiltration). Patients with 22q11.2 deletion syndrome may display hypocalcaemia in the neonatal period in conjunction with congenital heart disease, palatal abnormalities, immunodeficiency and learning difficulties [17] . Hypoparathyroidism is all the more striking when observed in association with renal failure. In three of our eight patients, hypoparathyroidism had been incorrectly diagnosed as primary or autoimmune. Two key messages of our report are that (i) hypoparathyroidism suggests potential HDR syndrome and should prompt both audiometry and renal investigation; and (ii) CKD associated with hypoparathyroidism is a virtually certain indicator of HDR syndrome. Early-onset sensorineural deafness is the most penetrant characteristic in HDR patients. Hearing loss is usually bilateral and more pronounced at high frequency, although of varying severity. All of our eight patients had a congenital hearing deficit, though unrecognized in one of them, thus illustrating the fact that sensorineural deafness should be tested for via audiometry, even if asymptomatic, when the clinical picture suggests HDR. Deafness may be symptomatic of other, distinct hereditary kidney disorders. Over 20 such disorders are cited in OMIM resources, the most prevalent of which being: (i) Alport syndrome (1-9/100 000), with persistent haematuria and progressive renal failure; (ii) branchio-oto-renal (BOR) syndrome (1-2/100 000), characterized by ear anomalies (outer, middle and inner), branchial fistulae and cysts, and renal malformations ranging from mild renal hypoplasia to bilateral renal agenesis; (iii) Fechtner syndrome (1-9/1 000 000), referring to the association of hereditary nephritis, sensorineural deafness and cataracts, and the triad of May-Hegglin anomaly (thrombocytopenia, large platelets and leukocyte inclusions); and (iv) Muckle-Wells syndrome (1/360 000), characterized by urticaria, deafness and renal amyloidosis (http://omim.org/). That said, none of these diseases is associated with hypoparathyroidism.
We observed highly diverse renal phenotypes in about 60% of patients with HDR (Table 2) . Renal abnormalities may be uni-or bilateral, or minor, and may even regress on their own with age, remaining undetected [3] . Phenotypes may also vary significantly among affected members of the same family, as illustrated by Patients #1 and #2. Patient #1 presented with ESRD at the age of 19 years, whilst his mother had only moderate CKD at the age of 58 years. VUR has been reported in <20% of patients so far, taking into account that cystography was performed in a considerably less systematic manner (Table 2) . HDR is now listed as one of the numerous syndromic congenital anomalies of the kidney and urinary tract (CAKUT) [18, 19] .
Interestingly, three out of our eight patients had nephroticrange proteinuria without haematuria, possibly due to FSGS secondary to nephron loss. FSGS was histologically proven in Patient #4. A very small number of cases of glomerular involvement have been reported in association with HDR [4, 10, 16, 20, 21] , although the link with the GATA-3 mutation remains unclear. Muroya et al. reported proteinuria and haematuria in a female patient [10] . Segmental, diffuse, proliferative glomerulonephritis was observed in a boy at the age of 4 years, in a multisystemic context, and immunofluorescence was not performed on the renal biopsy [21] . Lastly, renal prognosis seems favourable, with a reported ESRD rate of <10% ( Table 2 ). Three of our eight patients (40%) reached ESRD between the ages of 19 and 67 years, taking into account an obvious selection bias.
We also revealed congenital interventricular communication in one of our patients, which, although never reported in humans with HDR, has been observed in Gata-3-null mutant embryos [22] .
The GATA-3 gene consists of six exons distributed over 17 kb of genomic DNA and encodes the 444-amino-acid protein GATA-3 [23, 24] (Figure 2A ). This protein belongs to a family of dual zinc finger transcription factors that play a crucial role in vertebrate embryologic development [3] . Transcriptional regulators are DNA-binding proteins that bind to specific sequences called promoter-proximal sequences or enhancers. They subsequently interact to form complexes, and recruit RNA polymerase II, thus regulating DNA transcription. Kidney development is coordinated largely at the transcriptional level, which is illustrated by the fact that many gene mutations involving transcription factors are associated with kidney malformations [25, 26] . GATA-3 is expressed in the murine pronephric anlage, in conjunction with Pax2 and Pax8, and appears to act as a key regulator in morphogenesis and guidance of the nephric duct in the developing kidney [27] .
GATA-3 pathogenic missense variants are usually classified into three categories, based upon their functional effects on DNA-binding activity. Class 1 represents over 90% of all mutations in HDR syndrome and is characterized by a loss of DNA binding due to abnormalities involving C-finger. Class 2 leads to reduced DNA-binding affinity, as the defect involves N-finger. Finally, Class 3 exhibits normal DNA-binding affinity, but causes loss of interaction with FOG-2 or other cofactors, thereby altering the conformational change that occurs during DNA binding (Figure 2A and Ali et al. [16] ). The fact that reported GATA-3 mutations (missense and truncation) all result in the absence of DNA binding by the mutant GATA-3 protein indicates that haploinsufficiency of this gene accounts for most cases of HDR syndrome. Overexpression of GATA-3 resulting from gene duplication has also been associated with HDR [28] . No clear genotype-phenotype correlation has been determined yet [14] . A mutation in GATA-3 is identified in the vast majority of individuals with a combination of hypoparathyroidism, renal failure and deafness. In a very small number of individuals, usually without renal abnormalities, no mutation is observed [10, 11] .
In our study, analysis of patients showed five new diseasecausing variants. Three of them were single-nucleotide variants responsible for substitution of highly conserved amino acids within key motifs of the GATA-3 protein. A Class 1 variant was observed in Family 5 (c.1017C>G), leading to the loss of an essential cysteine coordinating zinc ions at the ZnF2 domain. A Class-2 mutation in Family 4 (c.856A>G) directly affected ZnF1 polarity. A Class 3 variant (c.896G>A) in Family 2 was predicted to affect DNA-binding properties by modifying the amino acid sequence of the linker region (Figure 2) . The final two variants were a point mutation (c.1051-2A>G) and small deletion (c.924þ4_924þ19del) located around splice site positions, both of which caused incorrect splicing and exon skipping. Perturbation of splicing may cause HDR syndrome via different mechanisms, such as (i) direct impact upon the protein amount with a halving of encoded GATA-3 or (ii) production of a truncated but functional peptide acting as a poison. Differentiation between haploinsufficiency and production of a dominantly negative mutant polypeptide remains difficult, despite previous RNA studies [29] . Furthermore, if haploinsufficiency could cause disease, and assuming that all the mutations described in this series would inactivate one gene allele, we would expect to observe little interfamilial phenotype variability. This was not the case for the two patients in Family 1. The cause of intrafamilial variability, still a point of contention, has been attributed to differences in environment or modifier genes. In our series, four out of five patients (Patients #3, #4, #5 and #8) had no family history of deafness, hypoparathyroidism or renal dysplasia. This suggests that de novo mutations may be common, although our series is small, and there was no systematic check-up performed in the patients' parents (as for Patient #1).
In summary, we demonstrate that HDR syndrome is associated with a highly variable inter-and intrafamilial phenotype. Diagnosis of HDR syndrome should be considered in any patient with hypoparathyroidism and deafness, whether associated with renal abnormalities or not. Identification of a mutation in the GATA-3 gene establishes the diagnosis, which is of particular relevance in cases of sporadic and incomplete presentation, facilitating genetic counselling.
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